Senses Disorder TRIZ Cases

Two ABCA4 expression cassettes use GP41-1 intein splicing to rebuild full-length protein while reducing harmful intermediates and immune risk.

Early intravenous IGF-1 and IGFBP-3 therapy helps premature infants reduce BPD risk while supporting lung maturation and respiratory outcomes.

Cineole forms a stable complex with amoxicillin to resist β-lactamase degradation and restore oral activity against ESBL bacteria.

Targeted residue changes in compstatin analogues improve C3 binding, complement inhibition, solubility, and potential half-life.

Controlled crystal forms of a hydrophobic quinazolinone reduce agglomeration in aqueous eye drops while preserving topical efficacy for ocular pain.

Targeting IGF-1R signaling reduces proptosis and clinical activity in thyroid eye disease while avoiding limits of older immunosuppressive therapies.

Rabbit CDR grafting improves anti-VEGF antibody stability and solubility while preserving strong binding for tumor and intraocular therapy.

A semi-permeable ocular implant uses CNTF-secreting cells to bypass the blood-retinal barrier and sustain therapy without immunosuppression.

Metal-modified cerium oxide nanoparticles help wound barriers kill pathogens while limiting inflammation and toxicity to healthy cells.

Controlled crystallization of a BTK inhibitor improves stability and solubility while enabling more effective pharmaceutical formulation.

A single composition merges ten bioactive compounds to simplify supplementation while supporting immunity and multi-organ disease prevention.

A 181 bp human opsin promoter boosts rod-selective transgene expression in AAV vectors while limiting cone and RPE off-target activity.

Engineered Fc regions that abolish FcRn binding clear soluble receptor ligands from the eye while limiting systemic exposure and toxicity.

Gene expression and skipped-exon biomarkers replace subjective grading to track FECD and glaucoma more accurately and reproducibly.

Peptide compositions using ZEP3 and ZEP4 reduce ROS and protect stressed eye cells, addressing degenerative vision loss beyond pressure-lowering therapies.

Specific anti-Tie2 antibodies activate Tie2 signaling to reduce ocular vascular permeability while preserving vascular integrity and Tie2 levels.

CRISPR/Cas9 and AAV constructs target the RS1 locus to restore functional retinoschisin expression and address failed XLRS gene therapy endpoints.

GCN4-modified HSV gH redirects propagation to target-expressing cells, enabling safer virus production without losing infectivity.

CFTR-activating compounds increase tear secretion and intestinal fluid transport to address limited relief in dry eye and constipation.

Viral vectors drive continuous anti-VEGF fusion protein expression in retinal cells to reduce injection frequency and improve durable wet AMD treatment.

Novel L. reuteri NK33 and B. adolescentis NK98 target the gut-brain axis to reduce inflammatory and depressive symptoms with fewer side effects.

Targeted PH20 amino acid changes reduce immunogenicity and preserve hyaluronidase activity under heat and phenolic preservatives.

IGF-1R antibodies block disease signaling in thyroid eye disease, reducing proptosis and clinical activity with more durable control than glucocorticoids.

Water-soluble DIPA compounds penetrate tissue and activate TRPM8 receptors to relieve blepharitis or conjunctivitis discomfort with less irritation.

Engineered ligand-binding and pore-domain substitutions enable selective exogenous activation of ion channels while limiting unwanted endogenous signaling.

Heparin-binding VEGFR-1 Fc-IgG fusion proteins extend intravitreal anti-VEGF half-life, reducing injection frequency in ocular angiogenic disorders.

Flexible VEGF antagonist dosing every 8 or 12 weeks after loading doses reduces injection burden while maintaining AMD disease control.

Pyridine azaspiro compounds target the muscarinic M4 receptor to improve therapeutic response while reducing dose-limiting adverse effects.

Compact AAV vectors use regulatable promoters and a recombination kill switch to control or silence ocular therapeutic gene expression.

Targets dysregulated calcium flux and maladaptive UPR signaling to protect hair cells, preserve auditory function, and prevent hearing loss.

Fatty acid esters of BHB and butanediol raise ketone levels without strict ketogenic diets, reducing side effects while supporting epilepsy care.

A PEG-based biphasic protein formulation keeps a VEGF antagonist partly precipitated for stable 30-day diffusion from an implant reservoir.

A chitosan-PCL bi-layer capsule enables intravitreal protein delivery for up to nine months while avoiding frequent injections and surgery.

Heterocyclic sulfonamide derivatives tune Kv1.3 binding kinetics and selectivity to improve treatment options across immune and metabolic disorders.

Using laminin-E8-coated substrates, this case boosts pluripotent stem cell differentiation into high-purity RPE cells with fewer culture steps and less cell loss.

Short peptoid dosing followed by 13+ drug-free days activates glucocorticoid signaling for lasting neuroprotection with fewer side effects.

Cryopreserved RPE cells use a ready-to-administer formulation that preserves viability after thawing and eases retinal therapy logistics.

Sleep-triggered bone-conduction therapy personalizes tinnitus treatment from patient data while avoiding daytime hearing interference.

By blocking IGF-1R signaling, these antibodies reduce proptosis and clinical activity scores where glucocorticoid therapy often relapses.

Using benzalkonium chloride in ophthalmic carriers helps treat COVID-19 conjunctivitis and reduce ocular SARS-CoV-2 transmission.

Codon-optimized AAV delivery of NDP preserves retinal and cochlear function in Norrie disease while lowering viral dose and uveitis risk.

Cyclic peptide derivatives target retinal neovascularization and edema, helping treat diabetic retinopathy and age-related macular degeneration.

Substituted benzofuran, benzopyrrole, and benzothiophene inhibitors regulate aberrant complement activity while limiting healthy tissue damage.

Structurally modified stilbene derivatives improve light stability while maintaining or enhancing AHR activity and enabling scalable preparation.

Short 3-7 amino acid oligopeptides improve solubility and production yield while inhibiting endothelial proliferation, migration, and vascular permeability.

Targeted VH and VL residue changes improve anti-HtrA1 binding affinity and inhibitory activity for AMD and related disorders.

A multivalent binder replaces hard-to-purify Wnt proteins by targeting FZD4, LRP5, and VEGF to activate Wnt signaling and reduce vascular permeability.